(Total Views: 444)
Posted On: 06/21/2019 10:16:17 PM
Post# of 145900
Correct me if I’m wrong but is my understanding that Leronlimab prevents mutation to the CD4 strain of HIV and if “81-88% of HIV-1 variants in treatment naïve patients are CCR5 tropic and that virtually all the remaining variants are dual/mixed tropic i.e., are able to utilize both CCR5 and CXCR4 coreceptors.” Then it is even more important that the newly exposed treatment naïve patients get on Leronlimab as soon as possible.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)